Vertex finally makes NICE with England's NHS on CF therapies, but runs into hiccup with preclinical kidney drug data
Days after Vertex Pharmaceuticals $VRTX secured a much earlier-than-anticipated FDA approval for its cystic fibrosis cocktail that covers the majority of patients — the drugmaker has finally reached a deal with authorities in England to cover the use of its cystic fibrosis drugs on the National Health Service (NHS).
Vertex has been haggling with UK’s cost-effectiveness watchdog NICE, which has refused to allow the company’s CF medicines on to England’s NHS until Vertex offers it a discount that would compel the agency to look favorably upon its cost-effectiveness.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,000+ biopharma pros reading Endpoints daily — and it's free.